Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
World Journal of Gastroenterology
|
May 20, 2005
Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B
Ping Liu, Yi-Yang Hu, Cheng Liu, et al.
World Journal of Gastroenterology
|
November 8, 2003
Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters
Lun-Gen Lu, Min-De Zeng, Mo-Bin Wan, et al.
World Journal of Gastroenterology
|
December 12, 2003
Relationship between clinical and pathologic findings in patients with chronic liver diseases
Lun-Gen Lu, Min-De Zeng, Yi-Min Mao, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|
October 27, 2004
[Oxymatrine in the treatment of chronic hepatitis B for one year: a multicenter random double-blind placebo-controlled trial]
Lun-gen Lu, Min-de Zeng, Yi-min Mao, et al.
Hepatology International
|
July 24, 2015
Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients
Ji-Dong Jia, Jin-Lin Hou, You-Kuan Yin, et al.
World Journal of Gastroenterology
|
October 16, 2004
Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study
Yi-Min Mao, Min-De Zeng, Lun-Gen Lu, et al.
World Journal of Gastroenterology
|
November 8, 2003
Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial
Lun-Gen Lu, Min-De Zeng, Yi-Min Mao, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|
May 26, 2007
[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]
Ji-dong Jia, Jin-lin Hou, You-kuan Yin, et al.
Theranostics
|
January 2, 2015
Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon
Feng-Qin Hou, Liu-Wei Song, Quan Yuan, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
World Journal of Gastroenterology
|
May 20, 2005
Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B
Ping Liu, Yi-Yang Hu, Cheng Liu, et al.
World Journal of Gastroenterology
|
November 8, 2003
Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters
Lun-Gen Lu, Min-De Zeng, Mo-Bin Wan, et al.
World Journal of Gastroenterology
|
December 12, 2003
Relationship between clinical and pathologic findings in patients with chronic liver diseases
Lun-Gen Lu, Min-De Zeng, Yi-Min Mao, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|
October 27, 2004
[Oxymatrine in the treatment of chronic hepatitis B for one year: a multicenter random double-blind placebo-controlled trial]
Lun-gen Lu, Min-de Zeng, Yi-min Mao, et al.
Hepatology International
|
July 24, 2015
Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients
Ji-Dong Jia, Jin-Lin Hou, You-Kuan Yin, et al.
World Journal of Gastroenterology
|
October 16, 2004
Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study
Yi-Min Mao, Min-De Zeng, Lun-Gen Lu, et al.
World Journal of Gastroenterology
|
November 8, 2003
Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial
Lun-Gen Lu, Min-De Zeng, Yi-Min Mao, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|
May 26, 2007
[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]
Ji-dong Jia, Jin-lin Hou, You-kuan Yin, et al.
Theranostics
|
January 2, 2015
Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon
Feng-Qin Hou, Liu-Wei Song, Quan Yuan, et al.
Page
of 3